Beyond type I interferon autoantibodies, various other autoantibodies have been reported in patients following SARS-CoV-2 infection, including those targeting annexin A2, angiotensin-converting enzyme 2 (ACE2), phospholipids, nuclear antigens, and other tissue-specific proteins, highlighting the broad autoimmune activation triggered by COVID-19 [5,6,7]. The gene discussed is ACE2; the disease is COVID-19.